HomeLGND • NASDAQ
add
Ligand Pharmaceuticals Inc
Previous close
$85.02
Day range
$85.17 - $86.90
Year range
$49.24 - $94.57
Market cap
1.55B USD
Avg Volume
163.04K
P/E ratio
16.44
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Revenue | 30.98M | -29.56% |
Operating expense | 19.14M | -1.33% |
Net income | 86.14M | 105.34% |
Net profit margin | 278.06 | 191.53% |
Earnings per share | 1.20 | -47.37% |
EBITDA | 11.75M | -49.61% |
Effective tax rate | 24.07% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 310.59M | 9.88% |
Total assets | 913.87M | 12.67% |
Total liabilities | 107.35M | -34.85% |
Total equity | 806.52M | — |
Shares outstanding | 17.96M | — |
Price to book | 1.89 | — |
Return on assets | 0.88% | — |
Return on capital | 0.98% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Net income | 86.14M | 105.34% |
Cash from operations | 18.73M | -44.82% |
Cash from investing | -3.78M | -135.79% |
Cash from financing | 12.18M | 1,671.87% |
Net change in cash | 27.14M | -37.93% |
Free cash flow | 27.58M | -2.01% |
About
Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenix Inc., the company went public in 1992. Initially focused on developing its own drugs, a period of turbulence in the early 2000s culminated in its CEO being ejected by the shareholders and provoked a change in focus to the acquisition of existing drugs and forming partnerships to develop them further.
The company has been the subject of multiple regulatory investigations, negative shorts-seller reports and class action lawsuits amid allegations of securities fraud.
In 2018 its CEO was listed among the top five highest paid CEOs in San Diego. Wikipedia
Founded
Sep 1987
Headquarters
Website
Employees
58
